Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and ...
LOS ANGELES, February 06, 2025--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company presented a talk during the plenary ...
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025 Kairos Pharma, Ltd. (NYSE ...
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that John Yu, MD, CEO and Chairman, will present a ...
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, ...
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback